Ligand to Report First Quarter 2023 Financial Results on May 4, 2023

Rhea-AI Summary

Ligand Pharmaceuticals (NASDAQ: LGND) will report its first quarter 2023 financial results after the U.S. financial markets close on May 4, 2023. A conference call is scheduled for 4:30 p.m. Eastern Time on the same day, featuring CEO Todd Davis, President Matt Korenberg, and CFO Tavo Espinoza. The call will provide insights into financial performance and general business updates.

Ligand's business model focuses on supporting mid to late-stage drug development through financing and licensing of its platform technologies, such as Captisol and Pelican. The company collaborates with leading pharmaceutical firms including Amgen, Merck, and Pfizer to generate revenue while maintaining a low corporate cost structure.

Positive

• Ligand's diversified portfolio supports multiple revenue streams from biotech and pharmaceutical product sales.
• Partnerships with major pharmaceutical companies enhance growth potential and revenue opportunities.
• The Captisol and Pelican platform technologies improve drug solubility and protein production efficiency.

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 4, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Speakers on the call will include Ligand’s CEO Todd Davis, President and COO Matt Korenberg, and CFO Tavo Espinoza.

Conference Call and Webcast Information

Date:	Thursday, May 4, 2023
Time:	4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Conference Call:	(888) 350-3452 (U.S. toll-free number)
	1 (646) 960-0369 (ex-U.S. toll dial-in number)
	Conference ID is 6501694
Webcast:	Live and replay webcasts of the call are available here.

About Ligand Pharmaceuticals Incorporated (“Ligand”)

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our platform technologies or both. Our business model generates value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding mid to late-stage drug development in return for economic rights and licensing our technology platforms to help partners discover and develop medicines. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to generate our revenue. We have two primary platform technologies that are available for outlicense – Captisol and Pelican. Our Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. For our Captisol partners, our team supplies the Captisol material needed for their programs. Our Pelican Expression Technology is a robust, validated, cost-effective and scalable platform for recombinant protein production that is especially well-suited for complex, large-scale protein production where traditional systems are not. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com.

Follow Ligand on Twitter @Ligand_LGND

We use Twitter and our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our Twitter account and our website, in addition to following our press releases, SEC filings, public conference calls and webcasts.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230424005882/en/

Ligand Pharmaceuticals Incorporated

Simon Latimer

investors@ligand.com

(858) 550-7766

Twitter: @Ligand_LGND

LifeSci Advisors

Bob Yedid

bob@lifesciadvisors.com

(516) 428-8577

Source: Ligand Pharmaceuticals Incorporated

FAQ

When will Ligand Pharmaceuticals report its first quarter 2023 earnings results?

Ligand Pharmaceuticals will report its first quarter 2023 earnings results on May 4, 2023.

What time is the Ligand Pharmaceuticals earnings call scheduled for?

The earnings call is scheduled for 4:30 p.m. Eastern Time on May 4, 2023.

Who will be speaking on the Ligand Pharmaceuticals conference call?

The conference call will feature CEO Todd Davis, President Matt Korenberg, and CFO Tavo Espinoza.

What are the main platform technologies of Ligand Pharmaceuticals?

Ligand Pharmaceuticals' main platform technologies are Captisol and Pelican.

How does Ligand Pharmaceuticals generate revenue?

Ligand generates revenue through partnerships, licensing of its technologies, and supporting drug development.